Celldex Therapeutics, Inc. (CLDX)

Celldex Therapeutics topped EPS expectations as revenue fell sharply year over year in the second fiscal quarter of 2026, reported August 6, 2026. EPS of -$0.94 topped the -$1.06 estimate by $0.12, while revenue fell 97% to about $0.0 million from $730,000.00 a year ago. With gross profit also about $0.0 million, the quarter produced an operating loss of roughly $80.6 million and a net loss of about $73.5 million, narrowing ~30% from a net loss of -$56.6 million a year ago, alongside EPS down 11% from -$0.85. The company remains focused on its antibody-based pipeline, including candidates such as CDX-0159, CDX-1140, and CDX-527, rather than marketed products. For the next period, consensus calls for EPS of -$1.02 on revenue of $725,750.00.